Signals
4Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Presbyopia pharmacological options widen past pilocarpine
Pilocarpine maturity, follow-on miotic-class programs, and emerging non-miotic mechanism programs are reshaping presbyopia management.
Inherited retinal disease gene therapy widens past RPE65
X-linked retinitis pigmentosa, choroideremia, and additional inherited retinal disease gene therapy programs are reading out.
Choroidal melanoma therapy options widen
Approved tebentafusp and emerging programs are creating the first systemic therapy options for metastatic choroidal melanoma.